Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSPGx: Pre-emptive Genotyping for Tacrolimus Dosing in Pretransplant CKD
NCT06701825Phase 4Recruiting
- Sponsor
- Hospital La Paz Institute for Health Research
- Start
- Jun 2025
- Primary completion
- Oct 2026
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of tacrolimus in kidney transplant rejection (2 arms), sponsored by Hospital La Paz Institute for Health Research. Primary endpoint: Tacrolimus concentrations levels at 4 days. Started Jun 2025; status: recruiting.
02
Drugs
tacrolimus
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT06701825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06701825.